<DOC>
	<DOCNO>NCT02054156</DOCNO>
	<brief_summary>The purpose trial compare effect treatment tobramycin solution inhalation ( TIS ) without azithromycin people cystic fibrosis ( CF ) age 6 month 18 year early isolation Pseudomonas aeruginosa ( Pa ) respiratory culture . Specimens blood sputum throat swab take study along pulmonary function test . Participants receive initial treatment TIS follow additional treatment TIS quarterly respiratory culture positive Pa addition either azithromycin placebo 18 month .</brief_summary>
	<brief_title>OPTIMIZing Treatment Early Pseudomonas Aeruginosa Infection Cystic Fibrosis</brief_title>
	<detailed_description>Cystic fibrosis ( CF ) lung disease begin first month life follow course recurrent low airway bacterial infection inflammation progression disease year decades variable pace . With development chronic lung infection , obstructive disease progressively worsen , ultimately lead respiratory failure . Pseudomonas aeruginosa ( Pa ) important pathogen infect CF low airway , acquisition early life associate pro-inflammatory effect , low lung function , poor nutritional outcome , decrease survival . Pseudomonas aeruginosa ( Pa ) infection cystic fibrosis ( CF ) airway typically proceed early infection chronic infection . Although study show minority individual CF spontaneously clear early Pseudomonas aeruginosa ( Pa ) infection , data multiple study suggest antibiotic superior treatment clear Pseudomonas aeruginosa ( Pa ) respiratory culture . Understanding transition period early chronic Pseudomonas aeruginosa ( Pa ) infection thus critical importance identify strategy prevent progression . The study assess clinical microbiologic efficacy safety azithromycin give three time weekly combination standardize tobramycin solution inhalation ( TIS ) therapy among child early Pseudomonas aeruginosa ( Pa ) . TIS therapy define initial eradication treatment 1-2 course 28 day TIS subsequent 28 day treatment time quarterly respiratory culture positive Pseudomonas aeruginosa ( Pa ) . Eligible participant randomize within one month Pseudomonas aeruginosa ( Pa ) positive culture receive one follow two treatment strategy 18 month : ( 1 ) oral placebo addition standardize TIS therapy , ( 2 ) oral azithromycin addition standardize TIS therapy . At first study visit , participant undergo physical examination review medical history . Lung function measure via spirometry ( child great four year age able perform spirometry ) , electrocardiogram ( ECG ) test conduct , hear ability measure via audiometry . Blood drawn laboratory test specimen obtain respiratory culture randomization study drug dispensing occur . Subsequent study visit take place Day 21 , Weeks 13 , 26 , 39 , 52 , 65 , 78 . At visit , participant undergo physical examination , spirometry test ( appropriate ) , respiratory specimen Pseudomonas aeruginosa ( Pa ) culture collect study drug dispense ( except Week 78 ) . Participants complete self-report parent-completed respiratory symptom questionnaires sign symptom evaluation perform visit . Repeat hear laboratory test perform Weeks 39 78 ECG test repeat Day 21 Week 78 . Participants require maintain medication diary throughout study .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Age ≥ 6 month ≤ 18 year Documentation CF diagnosis evidence one clinical feature consistent CF phenotype positive CF Newborn Screening result immunoreactive trypsinogen ( IRT ) IRT/DNA IRT/IRT one follow criterion : sweat chloride ≥ 60 milliequivalent ( mEq ) /liter quantitative pilocarpine iontophoresis test ( QPIT ) two wellcharacterized mutation cystic fibrosis transmembrane conductive regulator ( CFTR ) gene Abnormal nasal potential difference ( NPD ) ( change NPD response low chloride solution isoproteronol less 5 mV ) Documented new positive oropharyngeal , sputum low respiratory tract culture Pa within 30 day Baseline Visit ( Visit 1 ) , define : ) first lifetime document Pa positive culture ; b ) Pa recover least twoyear history Pa negative respiratory culture ( ≥ 1 culture/ year ) Clinically stable evidence significant respiratory symptom Baseline Visit would require administration intravenous anti pseudomonal antibiotic , oxygen supplementation , and/or hospitalization determine study physician Written inform consent obtain participant participant 's legal representative ( assent applicable ) ability participant comply requirement study Macrolide antibiotic use within 30 day Baseline Visit Initiation current course treatment TIS &gt; 14 day prior Baseline Visit Weight &lt; 6.0 kg Baseline Visit History aminoglycoside hypersensitivity adverse reaction inhale aminoglycoside History azithromycin hypersensitivity adverse reaction azithromycin allergy macrolide antibiotic History positive respiratory culture Nontuberculous mycobacteria ( NTM ) Burkholderia cepacia complex within 2 year Baseline Visit History unresolved , abnormal renal function ( define serum creatinine great 1.5 time upper limit normal age ) . History unresolved , abnormal liver function test ( define alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) great 4 time upper limit normal range ) history portal hypertension History unresolved , abnormal neutropenia ( ANC ≤ 1000 ) Abnormal ECG test Baseline Visit define QT interval correct ( QTc ) ( B ) ≥460 msec history ventricular arrhythmia History abnormal hearing sensitivity define hear threshold level &gt; 25 dB HL ( decibel Hearing Level ) visual reinforcement audiometry ( VRA ) frequency ( 5004000Hz ) &gt; 20 Decibels Hearing Level ( dBHL ) play standard audiometry two frequency ( 5008000Hz ) either ear , associate middle ear disease ( include infection ) flat ( Type B ) tympanogram New initiation chronic therapy ( great 21 day ) drug know prolong QT interval ( refer Appendix III ) within 30 day prior Baseline Visit coadministration nelfinavir oral anticoagulant Positive serum urine pregnancy test Baseline Visit ( perform female childbearing potential ) females child bear potential : pregnant , breastfeeding , unwilling use barrier contraception participation study Administration investigational drug within 30 day prior Baseline Visit Presence condition abnormality ( e.g. , preexist heart disease ) opinion site investigator would compromise safety participant quality data</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cystic fibrosis ( CF )</keyword>
	<keyword>Azithromycin</keyword>
	<keyword>Tobramycin solution inhalation ( TIS )</keyword>
	<keyword>Pseudomonas aeruginosa ( Pa )</keyword>
	<keyword>Early Pseudomonas aeruginosa infection</keyword>
	<keyword>Pulmonary exacerbation</keyword>
	<keyword>Standardized anti-pseudomonal therapy</keyword>
</DOC>